CRIS Current Research Information System

MARZOCCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.526
NA - Nord America 3.254
EU - Europa 2.242
AF - Africa 210
SA - Sud America 156
OC - Oceania 7
Totale 9.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.203
VN - Vietnam 1.384
CN - Cina 795
SG - Singapore 742
IT - Italia 479
GB - Regno Unito 459
SE - Svezia 317
DE - Germania 268
HK - Hong Kong 180
FR - Francia 141
IN - India 134
NL - Olanda 119
BR - Brasile 111
RU - Federazione Russa 103
KR - Corea 78
IE - Irlanda 74
UA - Ucraina 62
CI - Costa d'Avorio 57
FI - Finlandia 50
ZA - Sudafrica 47
JP - Giappone 38
SC - Seychelles 38
TG - Togo 38
EE - Estonia 33
BD - Bangladesh 31
BG - Bulgaria 31
CA - Canada 31
CH - Svizzera 30
JO - Giordania 28
PH - Filippine 24
AR - Argentina 22
TH - Thailandia 21
BE - Belgio 18
MX - Messico 15
NG - Nigeria 13
AT - Austria 11
CL - Cile 11
TW - Taiwan 11
IR - Iran 10
TR - Turchia 10
ES - Italia 9
PL - Polonia 9
SA - Arabia Saudita 8
GR - Grecia 7
ID - Indonesia 7
CZ - Repubblica Ceca 6
AU - Australia 5
IQ - Iraq 5
IL - Israele 4
KE - Kenya 4
DZ - Algeria 3
EC - Ecuador 3
MA - Marocco 3
MY - Malesia 3
PK - Pakistan 3
PY - Paraguay 3
CO - Colombia 2
GT - Guatemala 2
LT - Lituania 2
NO - Norvegia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GM - Gambi 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
NC - Nuova Caledonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
UY - Uruguay 1
UZ - Uzbekistan 1
YT - Mayotte 1
Totale 9.395
Salva come PNG Salva come JPEG
Città #
Singapore 527
Southend 394
Ashburn 375
Chandler 312
Ho Chi Minh City 307
Fairfield 274
Hanoi 237
Dong Ket 207
Hong Kong 175
Hefei 167
San Jose 160
Woodbridge 152
Seattle 136
Wilmington 127
Houston 123
Ann Arbor 116
Cambridge 116
Bologna 111
Beijing 107
Princeton 87
Dallas 84
Dublin 74
Seoul 74
New York 71
Santa Clara 69
Boardman 68
Abidjan 57
Lauterbourg 49
Helsinki 44
Turin 41
Lomé 38
Nanjing 37
Los Angeles 36
Westminster 36
Padova 34
Bremen 33
Haiphong 33
Milan 33
Sofia 31
Jacksonville 30
Tokyo 29
Berlin 28
Amman 27
Florence 27
Jinan 26
Da Nang 24
Munich 24
Frankfurt am Main 23
Bern 22
Hyderabad 22
Council Bluffs 21
São Paulo 20
Redondo Beach 19
Saint Petersburg 19
Shenyang 19
Biên Hòa 18
Brussels 18
Buffalo 18
San Diego 18
Guangzhou 17
Bengaluru 16
Redmond 16
Nanchang 15
Can Tho 14
Ha Long 14
Tianjin 14
Thái Nguyên 13
Abeokuta 12
Atlanta 12
Hebei 12
Orem 12
Quận Bình Thạnh 12
Redwood City 12
Zhengzhou 12
Nuremberg 11
Toronto 11
Brooklyn 10
Castelfranco Emilia 10
Fabriano 10
Falkenstein 10
Falls Church 10
Hangzhou 10
Paris 10
San Francisco 10
Shanghai 10
Amsterdam 9
London 9
Phoenix 9
Quận Một 9
Casalecchio di Reno 8
Chengdu 8
Des Moines 8
Düsseldorf 8
Johannesburg 8
Taizhou 8
Bắc Ninh 7
Changsha 7
Hải Dương 7
Medford 7
Ninh Bình 7
Totale 6.038
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 711
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 349
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 345
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 270
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 253
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 247
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 233
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 224
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 211
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 209
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 209
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 205
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 199
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 198
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 193
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 184
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 184
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 183
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 179
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 178
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 177
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 175
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 169
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 166
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 164
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 161
Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. 159
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 156
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 154
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 153
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 152
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 150
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 141
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 132
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 131
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 120
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 107
null 104
null 102
Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies 98
null 98
Proteasome inhibitors: Bortezomib in multiple myeloma 93
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 87
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 64
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 45
Totale 9.532
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.381
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.381
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021381 0 0 0 0 0 0 0 0 0 0 0 381
2021/20221.044 141 41 54 107 79 43 23 61 41 121 167 166
2022/20231.215 120 193 66 170 67 97 39 69 195 38 115 46
2023/2024394 24 42 23 40 39 106 16 35 6 18 28 17
2024/20251.197 65 108 91 101 150 54 106 43 16 176 76 211
2025/20263.363 325 755 281 223 310 148 260 92 578 228 96 67
Totale 9.532